EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Ming-Ming Zhao, Jian-Jun Yang, Kenji Hashimoto

Psychedelics · 2025

DOI: 10.61373/pp025i.0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychedelics, 2025. Verfasst von Ming-Ming Zhao und 2 weiteren Autor:innen. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory approval has been delayed over concerns about functional unblinding and protocol rigor. Early randomized, placebo-controlled studies also suggest benefits in autism spectrum disorder, eating disorders with comorbid PTSD, and anxiety related to life-threatening illness. Large epidemiological and naturalistic studies associate MDMA use with lower rates of depression, reduced suicidal ideation, and improved posttrauma coping, though causal inference is limited. MDMA-associated hyponatremia appears primarily linked to oxytocin-mediated antidiuresis (elevated plasma oxytocin without a copeptin rise), with arginine vasopressin potentially contributing under hyperthermia or polydipsia. In rodents, MDMA pretreatment enhances stress resilience and preserves adaptive neuroplasticity via a vagus-dependent gut–brain axis. This review traces MDMA's history; synthesizes evidence on acute risks (hyperthermia, hyponatremia, sympathomimetic overstimulation, and transient cognitive effects); and evaluates long-term outcomes and putative resilience mechanisms. Future work should standardize dosing and psychotherapeutic protocols, incorporate biomarkers to guide patient selection, and conduct adequately powered trials across emerging indications, alongside long-term safety monitoring and multidisciplinary collaboration.

Zitieren

APA

Zhao, M., Yang, J., & Hashimoto, K. (2025). MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions. Psychedelics. https://doi.org/10.61373/pp025i.0035

Vancouver

Zhao M, Yang J, Hashimoto K. MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions. Psychedelics. 2025. doi:10.61373/pp025i.0035

BibTeX
@article{Zhao2025,
  author = {Zhao, Ming-Ming and Yang, Jian-Jun and Hashimoto, Kenji},
  title = {MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions},
  journal = {Psychedelics},
  year = {2025},
  doi = {10.61373/pp025i.0035}
}
Kostenlos starten →